Oric Pharmaceuticals, Inc. — Director's Dealing 2025

Sep 24, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oric Pharmaceuticals, Inc. (ORIC)
CIK: 0001796280
Period of Report: 2025-09-22

Reporting Person: Chacko Jacob (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-09-22	Common Stock	S	125000	$10.7995	Disposed	656419	Direct

Footnotes

F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2025.

F2: Represents the weighted average share price of an aggregate total of 125,000 shares sold in the price range of $10.57 to $10.92 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: Includes 2,771 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan.

F4: The Reporting Person also holds restricted stock units (RSUs) representing a contingent right to receive 178,667 shares of ORIC Pharmaceuticals, Inc. Common Stock and stock options to purchase 3,378,000 shares of ORIC Pharmaceuticals, Inc. Common Stock, which were previously reported on Table II and are not included in this number.